Strong pipeline of business opportunities for life sciences company
ProBiotix Health, a life sciences business developing probiotics to support cardiometabolic health, says its current order book is at a record level.
In a trading update for the six months ended 30 June 2025, the Wakefield-headquartered company reports its gross revenues have risen 33 per cent to £1.34m (H1 2024: £1.01m), gross profits have also increased 33 per cent to £748,000 (H1 2024: £564,000), while EBITDA loss has been reduced by 59 per cent to £110,000 (H1 2024: £268,000 loss).
The business has also recorded a strong cash balance of £1.3m (H1 2024: £865,000).
Steen Andersen, CEO, said: “We are pleased with our first half performance, which continues to demonstrate strong momentum in the business, and leaves us well placed to continue our growth throughout the rest of the current financial year and beyond.
“We continue to innovate, as evidenced by the launch of two new menopause-focused women’s health concepts at the recent Vitafoods Nutraceutical Trade Show in Barcelona.
“Global demand for probiotics continues to grow, largely driven by a combination of lifestyle, health and demographic factors.
“Set against this, we enter the second half of the year with a strong pipeline of new business opportunities, a record order book and a balance sheet which can fully fund our growth aspirations.”
ProBiotix says it will release its interim results for the six months to 30 June 2025 on Monday 8 September 2025.
For more information and the source, visit: Strong pipeline of business opportunities for life sciences company | TheBusinessDesk.com